BEVITAL AS

“Supra-Omic”

Learn more about metabolomics and when to integrate with other omics

When to Choose Metabolomics ?

Metabolomics is the systematic study of small-molecule metabolites (typically <1.5 kDa) and provides the most immediate and sensitive readout of cellular physiology. Metabolomics has been called “supra-omic” because it sits closest to phenotype and integrates information from all upstream layers, and the environment. While genomics describes what could happen and proteomics describes what machinery is available, metabolomics provides a real-time snapshot of physiological and pathological states, describing what is happening right now in the biochemical network. Discordance between mRNA, protein, and metabolite levels is common due to translational control, enzyme kinetics, allosteric regulation, and substrate availability—factors that only metabolomics captures directly. In addition, metabolites are active regulators and not passive readouts, regulating genes, transcripts, and proteins by acting as signals and cofactors that influence transcription, RNA behavior, enzyme activity, post-translational modification, and protein stability.

The upper figure is an artistic visualization of the major omics layers, feedback loops and phenotype, annotated with the estimated number of molecular features for each omics. The Human Phenotype Ontology currently lists 18,000 phenotypic abnormalities.

Table 1 below provides a simple overview of the major omics layers, focusing on their biological functions and temporal resolution:

Omics LayerDefinition & FunctionTime Scale of ChangeTurnover RateInformation Level
GenomicsThe Blueprint: The complete set of DNA. Determines the organism’s potential and susceptibility.Static: Largely unchanging throughout an individual’s lifetime (except for somatic mutations/cancer).StablePotential: What can happen.
EpigenomicsThe Switch: Chemical modifications (methylation, acetylation) to DNA/histones that turn genes on/off without changing the sequence.Slow – Intermediate: Changes with age, lifestyle, and environmental exposure. Can act as a “cellular memory.”Days to YearsRegulation: How the blueprint is accessed.
TranscriptomicsThe Message: The set of RNA transcripts (mRNA). Reflects which genes are currently active/expressed.Fast: Responds to stimuli (drugs, stress) rapidly. Captures the intent to produce proteins.Minutes to HoursIntent: What the cell is trying to do.
ProteomicsThe Machinery: The set of expressed proteins. Executors of cellular function, signaling, and structure.Intermediate: Slower than transcripts. Proteins are more stable and accumulate post-translationally.Hours to DaysExecution: The functional machinery present.
MetabolomicsThe Result (Phenotype): Small molecules (<1.5 kDa) like sugars, lipids, amino acids. The end-product of all cellular processes.Instantaneous: Highly dynamic. Levels fluctuate in seconds to minutes in response to diet, exercise, or drugs.Seconds to MinutesState: What is actually happening right now.
MicrobiomicsThe Partner: The community of microorganisms (bacteria, viruses, fungi) living in/on the host (e.g., gut).Mixed: Composition (DNA) is relatively stable (months/years), but Function (metabolic output) changes rapidly.Hours (Function) to Months (Composition)Ecosystem: The external functional capacity.
Metabolomics as the Primary Approach

Choose metabolomics as primary layer when:

  • The phenotype is biochemical or functional
    Suspected alterations in energy metabolism, redox state, one‑carbon metabolism, lipid signaling, or amino‑acid pathways in disease or treatment response.
    Biomarker discovery where the readout should be close to physiology (e.g. acylcarnitines for mitochondrial function, bile acids for liver–gut axis, SCFAs for gut barrier/immune tone).

  • Need for an integrative, end‑point view
    To see the net result of genetics, epigenetics, transcription, translation, post‑translational regulation, microbiome activity, and environment on the biochemical state in one layer.
    For stratification and subtyping where symptomatically similar patients may have distinct metabolic endophenotypes despite overlapping genomic findings.

  • The exposure is environmental, dietary, pharmacological, or microbiome‑mediated
    Nutritional interventions, fasting/feeding cycles, exercise challenges, or xenobiotic exposure where the internal dose and downstream biochemical effects matter.
    Drug metabolism, off‑target effects, and host–drug–microbiome interactions (e.g. bacterial biotransformation of drugs, altered bile acid pools).

  • The key feature is rapid dynamics
    Time‑course studies of acute stress, circadian variation, or challenge tests (OGTT, clamp studies, meal tests) where metabolite trajectories capture functional capacity and regulation.
    Perturbation experiments in cell/animal models where flux and intermediate accumulation are central readouts.
Multiomics

In multiomics designs, metabolomics frequently acts as the functional validation layer of upstream changes: a genetic variant or protein abundance shift may suggest pathway perturbation, but only metabolite measurements confirm that flux has actually changed. Combination of metabolomics with other layers (Table 2.) is transformative, because: 

  • It separates signal from noise: Thousands of genes may be turned on, but only a few might actually alter cell metabolism. Metabolomics identifies which genetic changes are biologically relevant.

  • It captures the environment: Unlike the genome, which is static, the metabolome reacts to diet, drugs, and the microbiome. Combining them allows you to see how the environment modifies genetic programming (Epigenetics Metabolism).

  • It enables precision medicine: It moves medicine from treating “risk factors” to treating the actual molecular dysfunction driving the disease.

Combination withPrimary InsightKey MechanismMajor Applications
MicrobiomicsDistinguishes whether a blood marker comes from human cells or gut bacteria.Crosstalk:Microbial metabolites (like SCFAs) act as signaling molecules that regulate human genes.• Gut-Brain Axis (Alzheimer’s)
• Liver Disease (MASLD)
• Diabetes
ProteomicsValidates function. High protein levels don’t always mean high activity; metabolites confirm the enzyme is working.PTMs: Metabolites trigger “switches” (like phosphorylation) that turn proteins on/off.• Disease Subtyping (e.g., Alzheimer’s)
• Heart Failure prediction
• Functional Biology
EpigenomicsExplains how environment/diet physically alters DNA regulation.Cofactors: Epigenetic enzymes need fuel (metabolites like Acetyl-CoA) to modify DNA.• Cancer (Oncometabolites)
• Aging mechanisms
• Dietary impact on genes
GenomicsBridges the gap between genetic risk and actual disease.Intermediate Phenotypes: Traces the path from Gene to Metabolite to Disease.• Precision Medicine
• Prostate Cancer therapy
• Validating genetic variants
Metabolomics + Microbiomics

Integration of metabolomics and microbiomics is arguably the most transformative combination currently, particularly for understanding how “non-self” (microbes) influence “self” (host health). It is redefining our understanding of diabetes, liver disease, and neurodegeneration. Both omics are intimately linked and microbial communities produce a vast array of metabolites (e.g., SCFAs, bile acids, indoles) that modulate host physiology, immunity, and metabolism. Conversely, host-derived metabolites shape the composition and function of the microbiome.

  • Short-Chain Fatty Acids (SCFAs): Produced by microbial fermentation of dietary fibers, SCFAs (acetate, propionate, butyrate) regulate gut barrier integrity, immune responses, and energy metabolism. Butyrate, in particular, inhibits histone deacetylases (HDACs), linking microbial metabolism to host epigenetic regulation.
  • Bile Acids: Primary bile acids synthesized by the liver are converted to secondary bile acids by gut bacteria. These metabolites act as signaling molecules via nuclear receptors (e.g., FXR, TGR5), influencing lipid and glucose homeostasis, and inflammation.
  • Indoles and Tryptophan Metabolites: Microbial metabolism of tryptophan produces indoles, which activate host receptors (e.g., AhR, PXR), modulating gene expression, immunity, and gut barrier function.

Scroll to Top

Per Christian Eriksen

Øivind

Per Magne Ueland has been Professor at the University of Bergen 1987-2018. He is one of the founders of Bevital AS and the scientific advisor in Bevital since 2023. His interests includes biomarkers related to nutrition, inflammation, ageing and life-style related chronic diseases. Per is committed to the development of precise, high-throughput mass spectrometry methods, tailored for metabolic profiling of biobank specimens from large cohorts.

Marit holds a degree in chemical engineering from Bergen Ingeniørhøyskole, which is now part of the Western Norway University of Applied Sciences. She works with quantitative analysis and method development on LC-MS/MS at the laboratory of Bevital AS.

Ove completed a bachelor’s degree in Biomedical Laboratory Sciences at the Western Norway University of Applied Sciences in Bergen. With extensive experience in method development and expertise in GC-MS/MS, he specializes in optimizing analytical techniques for research-focused studies. At Bevital, Ove is dedicated to advancing laboratory methods and workflows, contributing to innovative research through precise and reliable analytical solutions.

Lene holds a bachelor’s degree in Biomedical Laboratory Science from the Western Norway University of Applied Sciences, where she is also completing her master’s degree in Medical Laboratory Technology. At Bevital, she works with GC-MS/MS analyses, focusing on accurate and reliable testing of biological samples. With her strong laboratory background, Lene is committed to delivering high-quality results that support medical research.

Klaus holds a PhD in physics from the University of Münster in Germany. He has over three decades of experience in Time-of-Flight mass spectrometry. He leverages his extensive expertise to provide customers with cutting-edge MALDI-MS analysis and the newest Olink Proteomics services.

Adrian holds a PhD in diabetes research, along with bachelor’s and master’s degrees in biomedical science and public health, respectively. With over 20 years of experience in laboratory science, he leads high-precision metabolite analyses and method development at Bevital. His expertise centers on quantifying biomarkers, metabolite classes, and metabolic pathways related to nutrition, cardiovascular and neurodegenerative diseases, and cancer. Adrian is committed to advancing research quality and actively collaborates nationally and internationally, leveraging targeted metabolomics to support innovative, multidisciplinary research.

Statistical power is the probability that a statistical test will correctly reject a false null hypothesis (H0​) when a specific alternative hypothesis (H1​) is true. H0​ is the null hypothesis, which states there is no effect or no difference. H1​ is the alternative hypothesis, which states there is a real effect or difference. Alpha (α) is the probability of a Type I error (a false positive), which is the risk of incorrectly rejecting the H0​ when it is actually true. You set this value before the experiment, commonly at 0.05. Beta (β) is the probability of a Type II error (a false negative), which is the risk of failing to reject the H0​ when it is actually false.

Power is calculated as 1−β. Increasing power means you are decreasing the probability of making a Type II error.

Several factors can be adjusted to increase the power of a statistical test:

  • Effect Size: This is the magnitude of the difference you are trying to detect. A larger effect size is easier to detect, thus increasing power. 

  • Sample Size: The number of observations in a study. A larger sample size provides more information about the population, reducing the margin of error and increasing the power to detect a true effect.

  • Variation: Refers to the spread or standard deviation of the data within the population. Less variation makes it easier to distinguish a real effect from random noise, thereby increasing power.

  • Alpha (): Increasing the alpha level (e.g., from 0.05 to 0.10) also increases power, but at the cost of a higher risk of a Type I error. This trade-off is often undesirable.

562 entries « 1 of 29 »
1.

Bakker, Lieke; Ramakers, Inez H G B; van Greevenbroek, Marleen M J; Backes, Walter H; Jansen, Jacobus F A; Schram, Miranda T; van der Kallen, Carla J H; Schalkwijk, Casper G; Wesselius, Anke; Ulvik, Arve; Ueland, Per M; Verhey, Frans R J; Eussen, Simone J P M; Köhler, Sebastian

The kynurenine pathway and markers of neurodegeneration and cerebral small vessel disease: The Maastricht Study Journal Article

In: J Neurol Sci, vol. 474, pp. 123522, 2025, ISSN: 1878-5883.

Abstract | Links | BibTeX

2.

Holthuijsen, Daniëlle D B; van Roekel, Eline H; Bours, Martijn J L; Ueland, Per M; Breukink, Stéphanie O; Janssen-Heijnen, Maryska L G; Konsten, Joop L; Keulen, Eric T P; McCann, Adrian; Brezina, Stefanie; Gigic, Biljana; Kok, Dieuwertje E; Ulrich, Cornelia M; Weijenberg, Matty P; Eussen, Simone J P M

Modeling how iso-caloric macronutrient substitutions are longitudinally associated with plasma kynurenines in colorectal cancer survivors up to 12 months post-treatment Journal Article

In: J Nutr Biochem, vol. 141, pp. 109910, 2025, ISSN: 1873-4847.

Abstract | Links | BibTeX

3.

Belen, Sergen; Patt, Nadine; Kupjetz, Marie; Ueland, Per M; McCann, Adrian; Gonzenbach, Roman; Bansi, Jens; Zimmer, Philipp

Vitamin B status is related to disease severity and modulated by endurance exercise in individuals with multiple sclerosis: a secondary analysis of a randomized controlled trial Journal Article

In: Am J Clin Nutr, vol. 121, no. 6, pp. 1403–1414, 2025, ISSN: 1938-3207.

Abstract | Links | BibTeX

4.

Dahl, Tuva B; Aftab, Friha; Prebensen, Christian; Berdal, Jan-Erik; Ueland, Thor; Barratt-Due, Andreas; Riise, Anne Ma Dyrhol; Ueland, Per Magne; Hov, Johannes R; Trøseid, Marius; Aukrust, Pål; Gregersen, Ida; Myhre, Peder L; Omland, Torbjørn; Halvorsen, Bente

Imidazole propionate is increased in severe COVID-19 and correlates with cardiac involvement Miscellaneous

2025, ISSN: 1532-2742.

Links | BibTeX

5.

Banjara, Sarala; Berggreen, Ellen; Igland, Jannicke; Åstrøm, Anne-Kristine; Midttun, Øivind; Bunæs, Dagmar; Sulo, Gerhard

Plasma levels of immune system activation markers Neopterin and Kynurenine-to-Tryptophan Ratio, and oral health among community-dwelling adults in Norway: a population-based, cohort study Journal Article

In: Acta Odontol Scand, vol. 84, pp. 218–225, 2025, ISSN: 1502-3850.

Abstract | Links | BibTeX

6.

Holthuijsen, Daniëlle D B; Rijnhart, Judith J M; Bours, Martijn J L; van Roekel, Eline H; Ueland, Per M; Breukink, Stéphanie O; Janssen-Heijnen, Maryska L G; Konsten, Joop L; Keulen, Eric T P; McCann, Adrian; Brezina, Stefanie; Gigic, Biljana; Ulrich, Cornelia M; Weijenberg, Matty P; Eussen, Simone J P M

Longitudinal associations of dietary intake with fatigue in colorectal cancer survivors up to 1 year post-treatment, and the potential mediating role of the kynurenine pathway Journal Article

In: Brain Behav Immun, vol. 126, pp. 144–159, 2025, ISSN: 1090-2139.

Abstract | Links | BibTeX

7.

Joisten, Niklas; Reuter, Marcel; Rosenberger, Friederike; Venhorst, Andreas; Kupjetz, Marie; Walzik, David; Schenk, Alexander; McCann, Adrian; Ueland, Per Magne; Meyer, Tim; Zimmer, Philipp

Exercise training restores longevity-associated tryptophan metabolite 3-hydroxyanthranilic acid levels in middle-aged adults Journal Article

In: Acta Physiol (Oxf), vol. 241, no. 5, pp. e70041, 2025, ISSN: 1748-1716.

Abstract | Links | BibTeX

8.

Jørgensen, Silje F; Braadland, Peder R; Ueland, Thor; Fraz, Mai S A; Michelsen, Annika E; Holm, Kristian; Osnes, Liv T; Trøseid, Marius; Ueland, Per Magne; Fevang, Børre; Aukrust, Pål; Hov, Johannes R

Tryptophan-kynurenine metabolites associate with inflammation and immunologic phenotypes in common variable immunodeficiency Journal Article

In: J Allergy Clin Immunol, 2025, ISSN: 1097-6825.

Abstract | Links | BibTeX

9.

Grytten, Elise; Laupsa-Borge, Johnny; Cetin, Kaya; Bohov, Pavol; Nordrehaug, Jan Erik; Skorve, Jon; Berge, Rolf K; Strand, Elin; Bjørndal, Bodil; Nygård, Ottar K; Rostrup, Espen; Mellgren, Gunnar; Dankel, Simon N

Inflammatory markers after supplementation with marine n-3 or plant n-6 PUFAs: A randomized double-blind crossover study Journal Article

In: J Lipid Res, vol. 66, no. 4, pp. 100770, 2025, ISSN: 1539-7262.

Abstract | Links | BibTeX

10.

Trollebø, Marte A; Tangvik, Randi J; Skeie, Eli; Nygård, Ottar; Eagan, Tomas M L; McCann, Adrian; Dierkes, Jutta

Metabolic profiles and malnutrition in hospitalized adults: A metabolomic cohort study Journal Article

In: JPEN J Parenter Enteral Nutr, vol. 49, no. 3, pp. 365–372, 2025, ISSN: 1941-2444.

Abstract | Links | BibTeX

11.

Valim, Valéria; Oliveira, Fabíola R; Miyamoto, Samira T; Serrano, Érica V; Balarini, Gabriela M; Tanure, Leandro A; Ferreira, Gilda A; Zandonade, Eliana; Brun, Johan G; Jonsson, Malin; Maeland, Elisabeth; Ulvik, Arve; Ueland, Per Magne; Jonsson, Roland; Mydel, Piotr M

Kynurenines and neopterin are interferon-gamma-inducible biomarkers for Sjögren's disease Journal Article

In: Rheumatology (Oxford), 2025, ISSN: 1462-0332.

Abstract | Links | BibTeX

12.

Wilson, Edward N; Umans, Jacob; Swarovski, Michelle S; Minhas, Paras S; Mendiola, Justin H; Midttun, Øivind; Ulvik, Arve; Shahid-Besanti, Marian; Linortner, Patricia; Mhatre, Siddhita D; Wang, Qian; Channappa, Divya; Corso, Nicole K; Tian, Lu; Fredericks, Carolyn A; Kerchner, Geoffrey A; Plowey, Edward D; Cholerton, Brenna; Ueland, Per M; Zabetian, Cyrus P; Gray, Nora E; Quinn, Joseph F; Montine, Thomas J; Sha, Sharon J; Longo, Frank M; Wolk, David A; Chen-Plotkin, Alice; Henderson, Victor W; Wyss-Coray, Tony; Wagner, Anthony D; Mormino, Elizabeth C; Aghaeepour, Nima; Poston, Kathleen L; Andreasson, Katrin I

Parkinson's disease is characterized by vitamin B6-dependent inflammatory kynurenine pathway dysfunction Journal Article

In: NPJ Parkinsons Dis, vol. 11, no. 1, pp. 96, 2025, ISSN: 2373-8057.

Abstract | Links | BibTeX

13.

Ramos-Rodríguez, Carla; Rojas-Gomez, Alejandra; Santos-Calderón, Luis A; Ceruelo, Santiago; Ríos, Lídia; Ueland, Per M; Fernandez-Ballart, Joan D; Salas-Huetos, Albert; Murphy, Michelle M

The l-Arginine pathway may act as a mediator in the association between impaired one-carbon metabolism and hypertension Journal Article

In: Biochimie, vol. 230, pp. 86–94, 2025, ISSN: 1638-6183.

Abstract | Links | BibTeX

14.

Svenningsson, Mads M; Svingen, Gard Ft; Ueland, Per M; Sulo, Gerhard; Bjørnestad, Espen Ø; Pedersen, Eva R; Dhar, Indu; Nilsen, Dennis W; Nygård, Ottar

Elevated plasma trimethyllysine is associated with incident atrial fibrillation Journal Article

In: Am J Prev Cardiol, vol. 21, pp. 100932, 2025, ISSN: 2666-6677.

Abstract | Links | BibTeX

15.

Damerell, Victoria; Klaassen-Dekker, Niels; Brezina, Stefanie; Ose, Jennifer; Ulvik, Arve; van Roekel, Eline H; Holowatyj, Andreana N; Baierl, Andreas; Böhm, Jürgen; Bours, Martijn J L; Brenner, Hermann; de Wilt, Johannes H W; Grady, William M; Habermann, Nina; Hoffmeister, Michael; Keski-Rahkonen, Pekka; Lin, Tengda; Schirmacher, Peter; Schrotz-King, Petra; Ulrich, Alexis B; van Duijnhoven, Fränzel J B; Warby, Christy A; Shibata, David; Toriola, Adetunji T; Figueiredo, Jane C; Siegel, Erin M; Li, Christopher I; Gsur, Andrea; Kampman, Ellen; Schneider, Martin; Ueland, Per M; Weijenberg, Matty P; Ulrich, Cornelia M; Kok, Dieuwertje E; and, Biljana Gigic

Circulating tryptophan-kynurenine pathway metabolites are associated with all-cause mortality among patients with stage I-III colorectal cancer Journal Article

In: Int J Cancer, vol. 156, no. 3, pp. 552–565, 2025, ISSN: 1097-0215.

Abstract | Links | BibTeX

16.

Fossdal, Guri; Braadland, Peder; Hov, Johannes Roksund; Husebye, Eystein Sverre; Folseraas, Trine; Ueland, Per Magne; Ulvik, Arve; Karlsen, Tom Hemming; Berge, Rolf Kristian; Vesterhus, Mette

Mitochondrial dysfunction and lipid alterations in primary sclerosing cholangitis Journal Article

In: Scand J Gastroenterol, vol. 60, no. 2, pp. 165–173, 2025, ISSN: 1502-7708.

Abstract | Links | BibTeX

17.

Walzik, David; Joisten, Niklas; Schenk, Alexander; Trebing, Sina; Schaaf, Kirill; Metcalfe, Alan J; Spiliopoulou, Polyxeni; Hiefner, Johanna; McCann, Adrian; Watzl, Carsten; Ueland, Per Magne; Gehlert, Sebastian; Worthmann, Anna; Brenner, Charles; Zimmer, Philipp

Acute exercise boosts NAD metabolism of human peripheral blood mononuclear cells Journal Article

In: Brain Behav Immun, vol. 123, pp. 1011–1023, 2025, ISSN: 1090-2139.

Abstract | Links | BibTeX

18.

Santos-Calderón, Luis A; Cavallé-Busquets, Pere; Ramos-Rodríguez, Carla; Grifoll, Carme; Rojas-Gómez, Alejandra; Ballesteros, Mónica; Ueland, Per M; Murphy, Michelle M

Folate and cobalamin status, indicators, modulators, interactions, and reference ranges from early pregnancy until birth: the Reus-Tarragona birth cohort study Journal Article

In: Am J Clin Nutr, vol. 120, no. 5, pp. 1269–1283, 2024, ISSN: 1938-3207.

Abstract | Links | BibTeX

19.

Anfinsen, Åslaug Matre; Myklebust, Vilde Haugen; Johannesen, Christina Osland; Christensen, Jacob Juel; Laupsa-Borge, Johnny; Dierkes, Jutta; Nygård, Ottar; McCann, Adrian; Rosendahl-Riise, Hanne; Lysne, Vegard

Serum concentrations of lipids, ketones and acylcarnitines during the postprandial and fasting state: the Postprandial Metabolism (PoMet) study in healthy young adults Journal Article

In: Br J Nutr, vol. 132, no. 7, pp. 851–861, 2024, ISSN: 1475-2662.

Abstract | Links | BibTeX

20.

Holthuijsen, Daniëlle D B; van Roekel, Eline H; Bours, Martijn J L; Ueland, Per M; Breukink, Stéphanie O; Janssen-Heijnen, Maryska L G; Keulen, Eric T P; Brezina, Stefanie; Gigic, Biljana; Peoples, Anita R; Ulrich, Cornelia M; Ulvik, Arve; Weijenberg, Matty P; Eussen, Simone J P M

Longitudinal associations of plasma kynurenines and ratios with fatigue and quality of life in colorectal cancer survivors up to 12 months post-treatment Journal Article

In: Int J Cancer, vol. 155, no. 7, pp. 1172–1190, 2024, ISSN: 1097-0215.

Abstract | Links | BibTeX

562 entries « 1 of 29 »

Olink Proteomics

Please fill out the fields below (*required).
We will respond to you ASAP.
Thank you!

Customized analyses

Please fill out the fields below (*required).
We will reply to you soon for a detailed project discussion.
Thank you for reaching out to Bevital!

Mix-and-Match

Please fill out the fields below (*required).
We will respond to you as soon as possible.

Ready-to-Run

Please fill out the fields below (*required).
We will respond ASAP.
Thank you!

Thanks for joining!

Get updates about new method developments, publications and comming events.